December 7. 2019 at 9:00 am
Venue: ELTE TTK 1117 Budapest, Pázmány Péter sétány 1/a, Eötvös Terem
István Greiner (Richter): Flow chemistry, benefits and shortcomings
Nowadays flow chemistry is a more and more popular topic in the synthetic chemistry journals. It is especially true if the article related to pharmaceutical industry and strict quality assured chemical processes. During the presentation unique features of this type of processes and couple of examples will be shared with the audience to give a deeper insight into the erveryday life of chemists working in this field.
Balázs Volk (Egis): Scale-up challenges in drug substance development - illustrated by Egis case studies
Development of the manufacturing processes of drug substances starting from laboratory scale through kilolab and pilot plant up to the plant-scale batch size is accompanied by numerous challenges in terms of chemistry, technology, engineering and process safety. The lecture provides some interesting recent case studies from the original and generic drug research and development activity of Egis Pharmaceuticals Plc., among others from the field of flow chemistry, cross-coupling and Diels-Alder reactions.
András Kotschy (Servier): The role of synthetic chemistry in drug discovery
The majority of the candidates addressing today's drug targets fall outside the conventional chemical space (MW>500), which leads to increased structural complexity. Synthetic methodology development is therefore a prerequisite of efficient drug discovery. The presentation dempstrates this interdependence through the story of a drug vcandidate's development.
József Répási (Soneas): Metathesis
Soneas in partnership with XiMo Ltd. is developing technologies for the production of pharmaceuticals, agrochemicals, flavour and fragrance chemicals based on metathesis since 2014. Soneas was the first company in the world producing in commercial scale the W and Mo based metathesis catalyst developed by the Nobel laurate Prof. Schrock and performs industrial scale metathesis reactions with the use of these catalysts.
István Puskás (Cyclolab): Exercises on three rings: highlights in the world of modified cyclodextrins
The three most common cyclodextrins are produced by enzymatic conversion of starch. By various synthetic procedures, these three compounds can be transformed into a common household cleaning agent in multiton scale, but some cyclodextrin derivatives were designed as critical components of analytical devices already sent by mankind to extraterrestial objects (such as Mars and comet 67P/Churyumov–Gerasimenko) searching for the traces of life. However, one may find the key use of cyclodextrin derivatives in pharmaceutical products of improved performance.
Peter Tátrai (Solvo): Drugs not only act, they also traffic: how transporter studies can inform drug development
In selecting and optimising a clinical lead, while general aspects of drug-likeness are always being kept in mind, most attention is understandably focussed on maximising the selective effect of the drug on its target. The structure of the drug, however, influences its pharmacokinetics including its interactions with drug transporter proteins just as much as its pharmacodynamics. Promising drug candidates can fail if their transporter-dependent flow at biological barriers defies expectations, or if they interfere with the transporter-mediated traffic of other important drugs. Solvo has been the industry leader in developing in vitro assays that help original drug research avoid such pitfalls by predicting drug-transporter interactions.
Thomas J.J. Müller: Diversity oriented one-pot synthesis of functional heterocycles - rapid strategies to novel dyes and kinase inhibitors
17. October 2019, MTA TTK
Carsten Sachse: Structural basis of p62/SQSTM1 polymers by electron Cryo-Microscopy
16. October 2019, ELTE TTK 6.511